Anavex Life Sciences Corp (AVXL)

[Millstone]

Interestingly, MS was mentioned in today's press release as a target for Anavex's molecules:

"The Neurotoxicity Research publication provides further insight on the mechanism of three Anavex sigma-1 receptor (S1R) agonists, ANAVEX®2-73, ANAVEX®1-41, and ANAVEX®3-71, which are all being studied in neurodegenerative diseases including Alzheimer’s disease (AD), Parkinson’s disease (PD) and multiple sclerosis (MS)."

So, only removed from the slide in the deck, not removed from the pipeline.

Hmmmm.